Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells 3,875 Shares of Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 3,875 shares of the business’s stock in a transaction on Friday, April 11th. The stock was sold at an average price of $7.57, for a total transaction of $29,333.75. Following the completion of the sale, the chief financial officer now directly owns 141,088 shares in the company, valued at approximately $1,068,036.16. This represents a 2.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, March 24th, Mark Leonard Singleton sold 5,479 shares of Bioventus stock. The shares were sold at an average price of $9.79, for a total value of $53,639.41.
• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The stock was sold at an average price of $10.19, for a total value of $66,214.62.

Bioventus Stock Down 2.3 %

Shares of Bioventus stock traded down $0.18 during trading on Tuesday, reaching $7.74. 429,619 shares of the company traded hands, compared to its average volume of 441,593. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm has a market capitalization of $634.25 million, a PE ratio of -12.69 and a beta of 0.92. The company has a 50 day moving average price of $9.52 and a 200-day moving average price of $10.70.

Wall Street Analyst Weigh In

BVS has been the subject of a number of recent analyst reports. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 target price on shares of Bioventus in a research report on Monday, March 17th. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Trading of Bioventus

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Bioventus by 18.7% during the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after buying an additional 388,174 shares during the period. Driehaus Capital Management LLC increased its holdings in shares of Bioventus by 33.7% during the fourth quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company’s stock valued at $11,758,000 after acquiring an additional 282,341 shares in the last quarter. American Century Companies Inc. raised its position in shares of Bioventus by 38.7% during the fourth quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock worth $9,289,000 after purchasing an additional 246,645 shares during the period. State Street Corp lifted its holdings in shares of Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after purchasing an additional 189,216 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Bioventus by 228.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock valued at $3,032,000 after purchasing an additional 176,442 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.